Objectives
Amyloid deposits are prevalent in osteoarthritis (OA)-affected joints. This study defined the dominant precursor and determined if the deposits affect chondrocyte functions.
Methods
Amyloid deposition in normal and OA human knee cartilage was determined by Congo red staining. Transthyretin (TTR) in cartilage and synovial fluid was analyzed by immunohistochemistry and western blotting. The effects of recombinant amyloidogenic and non-amyloidogenic TTR variants were tested in human chondrocyte cultures.
Results
Normal cartilage from young donors did not contain detectable amyloid deposits but 58% (7/12) of aged normal cartilage and 100% (12/12) of OA cartilage samples showed Congo red staining with green birefringence under polarized light. TTR, located predominantly at the cartilage surfaces, was detected in all OA and a majority of aged, but not young normal cartilage. Chondrocytes and synoviocytes did not contain significant amounts of TTR mRNA. Synovial fluid TTR levels were similar in normal and OA knees. In cultured chondrocytes, only an amyloidogenic TTR variant induced cell death, the expression of proinflammatory cytokines, and extracellular matrix degrading enzymes. The effects of amyloidogenic TTR on gene expression were mediated by in part by Toll-like receptor-4, Receptor for advanced glycation endproducts and p38 MAP kinase. TTR-induced cytotoxicity was inhibited by resveratrol, a plant polyphenol that stabilizes the native tetrameric structure of TTR.
Conclusions
The findings are the first to suggest that TTR amyloid deposition contributes to cell and extracellular matrix damage in articular cartilage in human OA and that therapies designed to reduce TTR amyloid formation might be useful.